ACC Guideline App Upgrade Includes Full Set of Prevention Guidelines

WASHINGTON (March 2, 2015) — The American College of Cardiology has launched version 2.0 of their Guideline Clinical App. With the addition of the healthy lifestyle and obesity guidelines, the app now contains the full set of clinical prevention guidelines released by ACC/American Heart Association in 2013. These additions expand the collection of clinical guidelines in the App which already includes guidelines on assessment of cardiovascular risk, treatment of blood cholesterol, atrial fibrillation, heart failure and valvular heart disease.

ACC’s Guideline Clinical App was developed to serve as a mobile home for all ACC/AHA guideline content and related tools. It includes an executive summary and top 10 points for each guideline, as well as a collection of interactive tools such as dosing calculators, scoring tools and algorithms useful to clinicians in determining recommended care. 

The original version of the app was launched in November 2014, with a second content release in December 2014. Version 2.0 of the app is part of plan to continuously add guideline content, upgrade functionality, and roll out fixes in response to user feedback. More guideline content and improvements are planned throughout 2015. ACC is conducting an impact and evaluation study to help inform future plans for the app. 

To date, the ACC Guideline Clinical App has more than 17,000 downloads. It is available for free and can be downloaded to a tablet or smartphone from iTunes and GooglePlay. 

The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit acc.org.

                                                                                    #  #  #

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.